Daily Cardiology Research Analysis
Three impactful cardiology studies advance precision care: tissue-specific cell-free DNA profiling predicts outcomes after LVAD implantation; a nationwide target trial emulation shows similar 1-year outcomes for ACURATE neo2 vs SAPIEN/Evolut when rigorous pre-/post-dilation is used; and a 160,523-patient registry confirms higher second-generation DES stent failure in diabetes, especially type 1. Together they refine risk stratification, procedural optimization, and post-PCI surveillance.
Summary
Three impactful cardiology studies advance precision care: tissue-specific cell-free DNA profiling predicts outcomes after LVAD implantation; a nationwide target trial emulation shows similar 1-year outcomes for ACURATE neo2 vs SAPIEN/Evolut when rigorous pre-/post-dilation is used; and a 160,523-patient registry confirms higher second-generation DES stent failure in diabetes, especially type 1. Together they refine risk stratification, procedural optimization, and post-PCI surveillance.
Research Themes
- Biomarkers and precision risk stratification in advanced heart failure
- Device evaluation and procedural optimization in TAVR
- Diabetes-associated risks in contemporary coronary stenting
Selected Articles
1. Cell-Free DNA Profiles End-Organ Injury and Predicts Outcomes in Advanced Heart Failure With Left Ventricular Assist Device Implantation.
In prospective multicenter cohorts, both nuclear and mitochondrial cfDNA were quantified; tissue-of-origin cfDNA was profiled via whole-genome bisulfite sequencing. LVAD implantation was associated with reductions in systemic and tissue-specific cfDNA, and cfDNA levels stratified post-LVAD risk, predicting adverse outcomes. These data support cfDNA as a noninvasive biomarker to profile end-organ injury and improve LVAD candidate risk stratification.
Impact: This study operationalizes tissue-specific cfDNA to noninvasively capture multi-organ injury and forecast outcomes in LVAD populations, a critical unmet need. It bridges molecular profiling with actionable risk stratification.
Clinical Implications: CfDNA (including tissue-of-origin signatures) could augment pre- and post-LVAD risk assessment, guide surveillance intensity, and identify patients at elevated risk for adverse outcomes. Implementation would require assay harmonization and prospective utility testing.
Key Findings
- Tissue-specific and systemic cfDNA were quantified in LVAD and non-LVAD HF cohorts using ddPCR and whole-genome bisulfite sequencing.
- LVAD implantation was associated with reductions in both systemic and tissue-of-origin cfDNA levels.
- Higher cfDNA levels predicted adverse post-LVAD outcomes, supporting cfDNA as a prognostic biomarker.
Methodological Strengths
- Prospective multicenter cohorts with paired pre/post-LVAD sampling
- Use of digital droplet PCR and tissue-of-origin mapping via whole-genome bisulfite sequencing
Limitations
- Exact follow-up duration and external validation cohorts were not detailed in the abstract
- Clinical utility thresholds and integration with existing risk models remain to be established
Future Directions: Standardize cfDNA assays and validate tissue-of-origin panels in larger, diverse LVAD populations; test cfDNA-guided management strategies in prospective interventional studies.
BACKGROUND: Adverse events after durable left ventricular assist devices (LVADs) pose a challenge to survival. However, there are limited risk stratification approaches. Plasma cell-free DNA (cfDNA) offers potential as a biomarker for assessing end-organ injury and risk stratification. METHODS: The study included a multicenter prospective cohort of patients with heart failure with and without LVAD (cohort 1), a separate cohort of patients with heart failure with paired samples before and after LVAD (cohort 2) implantation, and a comparator group of healthy controls. Nuclear cfDNA (ncfDNA) and mitochondrial cfDNA were quantified by digital droplet polymerase chain reaction. Tissue-specific cfDNA was identified using whole-genome bisulfite sequencing. Differences in cfDNA levels by LVAD use were assessed with the Wilcoxon rank-sum test or the paired
2. 1-Year Outcomes of TAVR With ACURATE neo2 vs SAPIEN/Evolut: A SWEDEHEART Target Trial Emulation Study.
Using a nationwide target trial emulation with rigorous pre-/post-dilation (predilation 100%, postdilation 45%), ACURATE neo2 showed no difference in 1-year composite outcomes versus SAPIEN/Evolut. The findings reconcile prior IDE trial signals by highlighting procedural technique as a key modifier of device performance.
Impact: This study informs device selection and procedural strategy in TAVR by demonstrating outcome equivalence with optimized technique, addressing discrepancies from prior RCTs.
Clinical Implications: Routine, systematic pre-dilatation and selective post-dilatation with appropriate balloon sizing may standardize outcomes across valve platforms. Programs should emphasize technique optimization and quality pathways alongside device choice.
Key Findings
- In 1,943 patients (644 ACURATE neo2; 1,299 SAPIEN/Evolut), 1-year composite outcome (death, stroke, HF hospitalization) was similar (adjusted HR 0.97; 95% CI 0.75–1.23).
- Rigorous dilation strategy: predilation in 100% and postdilation in 45% of ACURATE neo2 cases; undersized balloons (≤1 mm) commonly used.
- No differences in MI, PCI, or major bleeding; postdilation within ACURATE neo2 group was not associated with harm.
Methodological Strengths
- Nationwide registry with target trial emulation and balancing weighting
- Technique-detailed procedural data enabling causal interpretation of optimization
Limitations
- Observational emulation susceptible to residual confounding and unmeasured biases
- Generalizability may depend on operator experience with rigorous dilation protocols
Future Directions: Prospective pragmatic trials to test standardized dilation protocols across platforms; benchmarking registries to track adherence and outcomes; device-specific optimization algorithms.
BACKGROUND: The ACURATE IDE trial demonstrated increased death, stroke, and rehospitalization at 1 year with ACURATE neo2 transcatheter aortic valve replacement (TAVR) devices compared with control devices, possibly caused by suboptimal pre- and postdilatation. OBJECTIVES: The aim of this study was to investigate clinical outcomes of TAVR with ACURATE neo2 vs control valves using rigorous pre- and postdilatation. METHODS: The nationwide SWEDEHEART (Swedish Web-System for Enhancement and Development of Evidence-Based Care in Heart Disease Evaluated According to Recommended Therapies) registry to emulate a target trial comparing TAVR with the ACURATE neo2 vs SAPIEN or Evolut in Sweden, using the same inclusion and exclusion criteria as the investigational device exemption trial. The primary outcome was mortality, stroke, and heart failure hospitalization combined at 1 year. Adjustment by balancing weighting was used. RESULTS: The ACURATE neo2 was used in 644 patients (33%) and control prostheses in 1,299 patients (67%). With the ACURATE neo2, predilatation was used in 100% and postdilatation in 45% (n = 288). Balloons undersized ≤1 mm were used in 47% (n = 304) of the predilatations and 74% (n = 214) of the postdilatations with the ACURATE neo2. Median follow-up duration was 352 days (Q1-Q3: 193.5-365 days). There was no difference between the ACURATE neo2 and control at 12 months in the primary endpoint (adjusted HR: 0.97; 95% CI: 0.75-1.23), as individual outcomes, or for myocardial infarction, percutaneous intervention, or major bleeding. Within the ACURATE neo2 group, postdilatation was not significantly associated with adverse outcomes. CONCLUSIONS: There was no difference in clinical outcomes at 1 year between the ACURATE neo2 and the Evolut or SAPIEN valves. The discrepancy with the investigational device exemption trial findings may be explained by more rigorous pre- and postdilatation.
3. Coronary Stent Failure in Patients With Diabetes: A Nationwide Observational Study From SWEDEHEART.
In 160,523 patients receiving second-generation DES, stent failure risk was significantly higher in type 1 diabetes (adjusted HR 2.28) and type 2 diabetes (adjusted HR 1.35) versus non-diabetes over 4.5 years. Both in-stent restenosis and stent thrombosis contributed, and results were robust across sensitivity analyses.
Impact: This nationwide registry quantifies contemporary stent failure risk in diabetes with second-generation DES, directly informing surveillance and secondary prevention strategies.
Clinical Implications: Patients with diabetes—especially type 1—may warrant intensified follow-up, aggressive risk factor control, and tailored antithrombotic strategies after DES implantation. Trial testing of diabetes-specific stent and DAPT strategies is justified.
Key Findings
- Among 160,523 DES recipients, adjusted HR for stent failure was 2.28 (95% CI 1.97–2.65) in type 1 diabetes and 1.35 (95% CI 1.27–1.44) in type 2 diabetes vs non-diabetes.
- Both in-stent restenosis and stent thrombosis contributed to higher failure risk in diabetes.
- Sensitivity analyses addressing missingness and competing risk of death confirmed robustness.
Methodological Strengths
- Nationwide registry including all second-generation DES recipients over a decade
- Comprehensive adjustments with Cox models and multiple sensitivity analyses
Limitations
- Observational design cannot exclude residual confounding
- Lack of granular lesion, stent platform, and glycemic control details in the abstract
Future Directions: Evaluate mechanisms of failure by diabetes phenotype and glycemic control; test tailored stent platforms and antiplatelet strategies in randomized trials for diabetes populations.
OBJECTIVE: The association between diabetes and coronary stent failure is poorly established with second-generation drug-eluting stents (DES). We aimed to evaluate the risk of stent failure in patients with diabetes compared with those without diabetes after implantation of second-generation DES. RESEARCH DESIGN AND METHODS: All patients in Sweden who received second-generation DES between 2010 and 2020 were included and categorized into three groups: type 1 diabetes, type 2 diabetes, and without diabetes (reference group). The primary end point was stent failure, defined as in-stent restenosis or stent thrombosis. Adjusted hazard ratios (HRs) with 95% CIs were estimated by Cox regression models. Sensitivity analyses were performed to address missing data in covariates and account for death as a competing risk. RESULTS: The study included 160,523 patients: 2,406 with type 1 diabetes, 43,377 with type 2 diabetes, and 114,740 without diabetes. Seventy-one percent were male. Over a mean follow-up of 4.5 years, 5,510 stent failure events occurred. The fully adjusted HR for stent failure was 2.28 (95% CI 1.97-2.65) for patients with type 1 and 1.35 (95% CI 1.27-1.44) for patients with type 2 diabetes, compared with individuals without diabetes. Sensitivity analyses confirmed the robustness of the findings, with both in-stent restenosis and stent thrombosis contributing to the increased risk. CONCLUSIONS: We observed a significantly higher risk of second-generation DES stent failure in individuals with type 1 diabetes followed by those with type 2 diabetes, compared with individuals without diabetes. This elevated risk was attributed to both in-stent restenosis and stent thrombosis.